復星醫藥(600196.SH):子公司漢霖醫藥獲藥品生產許可證
格隆匯9月23日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物醫藥有限公司(“漢霖醫藥”)收到上海市藥品監督管理局頒發的《藥品生產許可證》,同意公司控股子公司上海復宏漢霖生物製藥有限公司作為上市許可持有人(委託方)、漢霖醫藥作為受託方生產注射用曲妥珠單抗(漢曲優®)。
此次漢霖醫藥獲發《藥品生產許可證》的場地系新增的注射用曲妥珠單抗(漢曲優®)生產基地,此前該產品已於上海市徐彙區生產基地開展商業化生產。
此次漢霖醫藥獲《藥品生產許可證》,有利於優化集團(即公司及控股子公司/單位,下同)生產資源分配,進一步擴大注射用曲妥珠單抗(漢曲優)®的產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.